These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 3203647)

  • 1. Bone lead, hypertension, and lead nephropathy.
    Wedeen RP
    Environ Health Perspect; 1988 Jun; 78():57-60. PubMed ID: 3203647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing bone lead content by chelation treatment in chronic lead poisoning: an in vivo X-ray fluorescence and bone biopsy study.
    Batuman V; Wedeen RP; Bogden JD; Balestra DJ; Jones K; Schidlovsky G
    Environ Res; 1989 Feb; 48(1):70-5. PubMed ID: 2492468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone lead in dialysis patients.
    Van de Vyver FL; D'Haese PC; Visser WJ; Elseviers MM; Knippenberg LJ; Lamberts LV; Wedeen RP; De Broe ME
    Kidney Int; 1988 Feb; 33(2):601-7. PubMed ID: 3129611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal effects of environmental and occupational lead exposure.
    Loghman-Adham M
    Environ Health Perspect; 1997 Sep; 105(9):928-38. PubMed ID: 9300927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of the CaNa2 EDTA Pb-mobilization test to detect occult lead nephropathy.
    Wedeen RP
    Uremia Invest; 1985-1986; 9(2):127-30. PubMed ID: 3939486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of lead in renal failure.
    Wedeen RP
    Clin Exp Dial Apheresis; 1982; 6(2-3):113-46. PubMed ID: 6758998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic renal failure with gout: a marker of chronic lead poisoning.
    Craswell PW; Price J; Boyle PD; Heazlewood VJ; Baddeley H; Lloyd HM; Thomas BJ; Thomas BW
    Kidney Int; 1984 Sep; 26(3):319-23. PubMed ID: 6439940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for epidemiologic studies of lead in bone in occupationally exposed populations.
    Landrigan PJ
    Environ Health Perspect; 1991 Feb; 91():81-6. PubMed ID: 2040253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of lead to hypertension with renal impairment.
    Batuman V; Landy E; Maesaka JK; Wedeen RP
    N Engl J Med; 1983 Jul; 309(1):17-21. PubMed ID: 6406892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone lead and the diagnosis of lead nephropathy.
    Wedeen RP; Van de Vyver FL; D'Haese PC; Visser WJ; Elseviers MM; Knippenberg LJ; Lamberts LV; De Broe ME; Batuman V; Schidlovsky G
    Contrib Nephrol; 1988; 64():102-8. PubMed ID: 3141113
    [No Abstract]   [Full Text] [Related]  

  • 11. Lead nephropathy, gout, and hypertension.
    Batuman V
    Am J Med Sci; 1993 Apr; 305(4):241-7. PubMed ID: 8475950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo bone lead measurements: a rapid monitoring method for cumulative lead exposure.
    Wielopolski L; Ellis KJ; Vaswani AN; Cohn SH; Greenberg A; Puschett JB; Parkinson DK; Fetterolf DE; Landrigan PJ
    Am J Ind Med; 1986; 9(3):221-6. PubMed ID: 3963004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lead and the kidney: nephropathy, hypertension, and gout.
    Perazella MA
    Conn Med; 1996 Sep; 60(9):521-6. PubMed ID: 8908777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lead in vertebral bone biopsies from active and retired lead workers.
    Schütz A; Skerfving S; Christoffersson JO; Ahlgren L; Mattson S
    Arch Environ Health; 1987; 42(6):340-6. PubMed ID: 3439810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone lead and blood lead levels in relation to baseline blood pressure and the prospective development of hypertension: the Normative Aging Study.
    Cheng Y; Schwartz J; Sparrow D; Aro A; Weiss ST; Hu H
    Am J Epidemiol; 2001 Jan; 153(2):164-71. PubMed ID: 11159162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Determination of lead in hydride form in bone biopsies of patients with long past lead poisoning].
    Kijewski H; Lowitz HD
    Arch Toxicol; 1982 Sep; 50(3-4):301-11. PubMed ID: 7149993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic lead nephropathy in Queensland: alternative methods of diagnosis.
    Craswell PW; Price J; Boyle PD; Heazlewood VJ; Baddeley H; Lloyd HM; Thomas BJ; Thomas BW; Williams GM
    Aust N Z J Med; 1986 Feb; 16(1):11-9. PubMed ID: 3085647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body burdens of lead in hypertensive nephropathy.
    Osterloh JD; Selby JV; Bernard BP; Becker CE; Menke DJ; Tepper E; Ordonez JD; Behrens B
    Arch Environ Health; 1989; 44(5):304-10. PubMed ID: 2510613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical application of in vivo tibial K-XRF for monitoring lead stores.
    Wedeen RP; Ty A; Udasin I; Favata EA; Jones KW
    Arch Environ Health; 1995; 50(5):355-61. PubMed ID: 7574889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. X-ray fluorescence: issues surrounding the application of a new tool for measuring burden of lead.
    Hu H; Milder FL; Burger DE
    Environ Res; 1989 Aug; 49(2):295-317. PubMed ID: 2753011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.